Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 24, Number 7—July 2018

Research

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 20151

Gili Regev-YochayComments to Author , Klaris Reisenberg, Michal Katzir, Yonit Wiener-Well, Galia Rahav, Jacob Strahilevitz, Valery Istomin, Evgenia Tsyba, Avi Peretz, Shirley Khakshoor, Ron Dagan, on behalf of the Israeli Adult Invasive Pneumococcal Disease Group
Author affiliations: Sheba Medical Center, Ramat Gan, Israel (G. Regev-Yochay, G. Rahav, S. Khakshoor); Tel Aviv University, Tel Aviv, Israel (G. Regev-Yochay, M. Katzir, G. Rahav); Soroka Medical Center, Beersheba, Israel (K. Reisenberg); Bar-Ilan University, Safed, Israel (K. Reisenberg, A. Peretz); Meir Medical Center, Kfar Saba, Israel (M. Katzir); Shaare Zedek Medical Center, Jerusalem, Israel (Y. Wiener-Well); Hadassah-Hebrew University, Jerusalem (J. Strahilevitz); Hillel Yaffe Medical Center, Hadera, Israel (V. Istomin); Barzilai Medical Center, Ashkelon, Israel (E. Tsyba); Baruch Padeh Medical Center, Tiberias, Israel (A. Peretz); Ben-Gurion University of the Negev, Beersheba (R. Dagan)

Main Article

Figure 2

Proportion ceftriaxone-nonsusceptible isolates among all Streptococcus pneumoniae isolates acquired from patients with invasive pneumococcal disease, by 2-year period, Israel, July 1, 2009–June 30, 2015. Ceftriaxone-nonsusceptible isolates were those that could grow at a concentration above ceftriaxone’s MIC (>1 µg/mL). *In 2009–2011, the 1 ceftriaxone-nonsusceptible isolate was serotype 14. †In 2011–2013, the 5 ceftriaxone-nonsusceptible isolates included 2 of serotype 19F and 1 each of sero

Figure 2. Proportion ceftriaxone-nonsusceptible isolates among all Streptococcus pneumoniae isolates acquired from patients with invasive pneumococcal disease, by 2-year period, Israel, July 1, 2009–June 30, 2015. Ceftriaxone-nonsusceptible isolates were those that could grow at a concentration above ceftriaxone’s MIC (>1 µg/mL). *In 2009–2011, the 1 ceftriaxone-nonsusceptible isolate was serotype 14. †In 2011–2013, the 5 ceftriaxone-nonsusceptible isolates included 2 of serotype 19F and 1 each of serotypes 19A, 34, and 23B. ‡In 2013–2015, the ceftriaxone-nonsusceptible isolates were serotypes 23F (n = 2) and 19A (n = 3), and 1 was not typeable.

Main Article

1Some results from this study were presented at the 10th International Symposium on Pneumococci and Pneumococcal Diseases, June 26–30, 2016, Glasgow, Scotland.

2Additional members of the Israeli Adult Invasive Pneumococcal Disease Group are listed at the end of this article.

Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external